Disease · MONDO_0005920

Plasmodium falciparum malaria

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Plasmodium falciparum malaria. Diseases, record MONDO_0005920. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005920

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Plasmodium falciparum malaria; Open Targets
Open Targets ID: MONDO_0005920; Open Targets
Other names: Falciparum malaria (disorder), Malaria fever, subtertian, Malaria, Falciparum, Plasmodium falciparum malaria, unspecified, Plasmodium falciparum malaria, unspecified (disorder), falciparum malaria, falciparum malaria [malignant tertian], malignant tertian fever (finding); Open Targets
Disease Ontology: DOID:14067; Disease Ontology
MeSH: D016778; MeSH
NCI Thesaurus: C34798; NCI Thesaurus
Highest stage of its drugs: Approval, for 2 of its 45 drugs, from DailyMed; Open Targets

Drugs45

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
QUININE SULFATE	CHEMBL2359966	Small molecule	Approval	DailyMed	8	1	1	Drugs and targets
MEFLOQUINE HYDROCHLORIDE	CHEMBL535650	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
ARTESUNATE	CHEMBL361497	Small molecule	Phase 3	ClinicalTrials.gov	37	37	37	Drugs and targets
ARTEMETHER	CHEMBL566534	Small molecule	Phase 3	ClinicalTrials.gov	29	29	29	Drugs and targets
LUMEFANTRINE	CHEMBL38827	Small molecule	Phase 3	ClinicalTrials.gov	29	29	29	Drugs and targets
PIPERAQUINE	CHEMBL303933	Small molecule	Phase 3	ClinicalTrials.gov	22	22	22	Drugs and targets
ARTENIMOL	CHEMBL307261	Small molecule	Phase 3	ClinicalTrials.gov	20	20	20	Drugs and targets
PRIMAQUINE	CHEMBL506	Small molecule	Phase 3	ClinicalTrials.gov	15	15	15	Drugs and targets
AMODIAQUINE	CHEMBL682	Small molecule	Phase 3	ClinicalTrials.gov	13	13	13	Drugs and targets
LUMEFANTRINE CO-ARTEMETHER	CHEMBL4297927		Phase 3	ClinicalTrials.gov	13	13	2	Drugs and targets

1 to 10 of 45

See all 45 drugs

Targets12

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
FAAH	Fatty-acid amide hydrolase 1	1	Anandamide amidohydrolase inhibitor	Unknown	https://conductscience.org/library/genes/2166	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
MMP1	Interstitial collagenase	1	Matrix metalloproteinase-1 inhibitor	Unknown	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	1	Matrix metalloproteinase 13 inhibitor	Unknown	https://conductscience.org/library/genes/4322	Drugs and targets
MMP7	Matrilysin	1	Matrix metalloproteinase 7 inhibitor	Unknown	https://conductscience.org/library/genes/4316	Drugs and targets
MMP8	Neutrophil collagenase	1	Matrix metalloproteinase 8 inhibitor	Unknown	https://conductscience.org/library/genes/4317	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor beta	1	Platelet-derived growth factor receptor beta inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets
PTGS1	Cyclooxygenase	1	Cyclooxygenase inhibitor	Unknown	https://conductscience.org/library/genes/5742	Drugs and targets

1 to 10 of 12

See all 12 targets

Trials94

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00422084	Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients	Phase 3	1,272	2021-09-20	Malaria	ARTEMETHER, ARTESUNATE, LUMEFANTRINE, LUMEFANTRINE CO-ARTEMETHER, PYRONARIDINE	Its record names the disease	ClinicalTrials.gov
NCT00403260	Pyronaridine - Artesunate (3:1) Versus Mefloquine Plus Artesunate in Plasmodium Falciparum Malaria Patients	Phase 3	1,271	2021-09-17	Falciparum Malaria	ARTESUNATE, MEFLOQUINE, PYRONARIDINE	Its record names the disease	ClinicalTrials.gov
NCT03167242	Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria	Phase 2	524	2022-02-10	Acute Uncomplicated Plasmodium Falciparum Malaria	ARTEMETHER, GANAPLACIDE, LUMEFANTRINE	Its record names the disease	ClinicalTrials.gov
NCT02083380	Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria.	Phase 2/3	448	2017-01-30	Uncomplicated Plasmodium Falciparum Malaria	ARTEFENOMEL, PIPERAQUINE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03355664	Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam	Phase 3	310	2022-07-15	Malaria, Falciparum	AMODIAQUINE, ARTEMETHER, LUMEFANTRINE	Its record names the disease	ClinicalTrials.gov
NCT04222088	TES of Artemether-lumefantrine for Pf and Chloroquine for Pv in the Philippines From 2013-2014		159	2023-02-23	Malaria, Falciparum Malaria, Vivax Malaria, Malaria Recrudescence	ARTEMETHER, CHLOROQUINE, LUMEFANTRINE, LUMEFANTRINE CO-ARTEMETHER, PRIMAQUINE	Its record names the disease	ClinicalTrials.gov
NCT01258049	Superiority of ArTiMist Versus Quinine in Children With Severe Malaria	Phase 3	151	2014-02-28	Plasmodium Falciparum Malaria	ARTEMETHER	Its record names the disease	ClinicalTrials.gov
NCT03660839	Study to Investigate the Clinical and Parasiticidal Activity and Pharmacokinetics of Different Doses of Artefenomel and Ferroquine in Patients With Uncomplicated Plasmodium Falciparum Malaria	Phase 2	140	2020-12-02	Plasmodium Falciparum Infection	ARTEFENOMEL	Its record names the disease	ClinicalTrials.gov
NCT02851108	Methylene Blue Against Falciparum Malaria in Burkina Faso	Phase 2	100	2020-03-25	Malaria, Falciparum	AMODIAQUINE, ARTESUNATE, METHYLENE BLUE, PRIMAQUINE	Its record names the disease	ClinicalTrials.gov
NCT01753323	Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection	Phase 2	43	2015-08-19	Malaria	GANAPLACIDE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 94

See all 94 trials

Comparisons in its trials27

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
PA Group vs AL Group: deaths from any cause	0 of 849	0 of 423	1,272	NCT00422084	Trial comparisons
PA Group vs AL Group: serious adverse events	3 of 849	2 of 423	1,272	NCT00422084	Trial comparisons
Pyronaridine - Artesunate vs Mefloquine Plus Artesunate: deaths from any cause	0 of 848	0 of 423	1,271	NCT00403260	Trial comparisons
Pyronaridine - Artesunate vs Mefloquine Plus Artesunate: serious adverse events	6 of 848	3 of 423	1,271	NCT00403260	Trial comparisons
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: Polymerase Chain Reaction Corrected Efficacy Defined as Adequate Clinical and Parasitological Response (ACPR) by Study Arm	146 of 154	151 of 156	310	NCT03355664	Trial comparisons
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: Number of Severe Adverse Events by Study Arm	2 of 154	5 of 156	310	NCT03355664	Trial comparisons
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: deaths from any cause	0 of 154	0 of 156	310	NCT03355664	Trial comparisons
Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24 vs Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24: serious adverse events	2 of 154	5 of 156	310	NCT03355664	Trial comparisons
Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: deaths from any cause	0 of 84	0 of 75	159	NCT04222088	Trial comparisons
Artemether-lumefantrine (Coartem™) + Primaquine vs Chloroquine + Primaquine: serious adverse events	0 of 84	0 of 75	159	NCT04222088	Trial comparisons

1 to 10 of 27

See all 27 comparisons in its trials

Papers from its trials80

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26654101	RESULT	2	PubMed
22475593	RESULT	1	PubMed
20417857	RESULT	1	PubMed
16960779	RESULT	1	PubMed
15330070	RESULT	1	PubMed
15155976	RESULT	1	PubMed
42994442	DERIVED	2	PubMed
42462745	DERIVED	1	PubMed
41121745	DERIVED	1	PubMed
39701119	DERIVED	1	PubMed

1 to 10 of 80

See all 80 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005920

GET https://conductscience.org/api/diseases/v1/MONDO_0005920/drugs?page=2

API reference For AI assistants